SSX2 and neoplasm: Furthermore, SSX2 was specifically enriched in the CD45−/EpCAM+/CD63+ subpopulation, which marks prostate-specific circulating tumor cells [23] while differentiating from erythroid progenitor CD45−/EpCAM+ cells (Figure 1E).